While targeting FASN presents a promising strategy, there are several challenges. One major issue is the potential toxicity to normal tissues that also require FASN activity for lipid metabolism. Additionally, cancer cells may develop resistance to FASN inhibitors through compensatory metabolic pathways. Therefore, combination therapies that target multiple metabolic pathways may be necessary to overcome resistance and achieve durable responses.
